Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $20.2M (cash outflow) fell 38.2% year over year, behind the -19.9% change in trailing-twelve-month net income. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$62.77M (-37.2%) for the fiscal year ending Dec 2026, a slowdown from the +1.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.2M-3.5% QoQ
- Last fiscal yearDec 2025
- -$99.96M+1.7% YoY
- LTMMar 2026
- -$87.5M-19.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -38.2% | -10.5% | +27.7 pp |
| 1 year | +1.7% | -37.2% | -38.9 pp |
| 3-year CAGR | +19.0% | -30.1% | -49.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (99.96M) USD
- Year-over-year change
- -1.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (99.96M) | -1.7% |
| FY2024 | 2024-12-31 | (98.33M) | -48.1% |
| FY2023 | 2023-12-31 | (66.39M) | -12.0% |
| FY2022 | 2022-12-31 | (59.28M) | -17.1% |
| FY2021 | 2021-12-31 | (50.62M) | — |
Net Income vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's LTM Mar 2026 net income of $87.5M is the 8th largest of the 11 companies compared; the peer median is $150.92M.
- Its year-over-year change of -19.9% is the 9th highest of 10, against a peer median of +47.3%.
- Over three fiscal years its annual growth of +19.0% compares with a peer median of +35.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B | +146477.0% | +53.5% | — | |
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
| LTM Mar 2026 | $167.47M | +47.3% | +15.1% | — | |
| LTM Mar 2026 | $166.01M | +74.3% | +67.3% | — | |
| LTM Mar 2026 | $156.4M | +7.6% | +77.4% | — | |
| LTM Mar 2026 | $145.44M | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $87.5M | -19.9% | +19.0% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M | +17.3% | +35.2% | — |
| LTM Mar 2026 | $35.71M | -24.3% | -0.3% | 7142.0% | |
| LTM Mar 2026 | $5.23M | +106.0% | -28.4% | 2.4% | |
| Peer median (excluding LXEO) | $150.92M | +47.3% | +35.2% | 319.6% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 379K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 386K | 1.78M | 3.04M | 12.47M | 12.13M |
| Change in Working Capital | 6.04M | 1.79M | 1.48M | 2.73M | (9.52M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.02M | (426K) | (180K) | 2.38M | (1.56M) |
| Other Working Capital | 3.03M | 2.22M | 1.66M | 351K | (7.95M) |
| Other Non-Cash Items | 0 | 0 | 530K | (23K) | (1.6M) |
| Operating Cash Flow | (44.18M) | (54.56M) | (59.5M) | (81.15M) | (98.56M) |
| Capital Expenditures | (188K) | (901K) | (165K) | (481K) | (397K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (93.6M) | (195.4M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 105.53M |
| Other Investing Activities | 0 | (229K) | (50K) | 0 | 17K |
| Investing Cash Flow | (188K) | (901K) | (165K) | (94.08M) | (90.25M) |
| Debt Repayment | 0 | (163K) | 3.58M | (410K) | (533K) |
| Common Stock Issued | 170K | 332K | 100.25M | 88.71M | 217.33M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (203K) | 332K | (35K) | 491K | 0 |
| Financing Cash Flow | 150.86M | 189K | 103.79M | 88.78M | 216.8M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.49M | (55.27M) | 44.13M | (86.45M) | 27.98M |
| Free Cash Flow | (44.37M) | (55.46M) | (59.66M) | (81.63M) | (98.96M) |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.